Alzheimer's Props Lilly Growth Prospects After Evacetrapib
This article was originally published in Scrip
Eli Lilly & Co. is embarking on a rough forecast period, with analysts predicting a continuing decline in sales for the firm's central nervous system (CNS) franchise. However, calmer seas might be ahead if the ongoing trial for its Alzheimer's disease (AD) antibody solanezumab yields positive results and if growth products can reach their targets by year 2019.
Register for our free email digests: